Emocog Secures $30M Series B Funding to Accelerate Digital Therapeutics for Cognitive Health

Emocog, a pioneering digital therapeutics company, proudly announces the successful raise of $30 million in its latest funding round. Established in 2021, Emocog has rapidly established itself as a leader in creating digital health solutions, collaborating with the finest experts to develop innovative SaMDs (Software as a Medical Device). The company is at the forefront of developing advanced software-based cognitive training programs for patients with Mild Cognitive Impairment, as well as precision diagnostic tools for early-stage dementia. With a dedicated team of professionals spanning various specialties, Emocog is already partnered with industry giants such as Kakao, Naver, and Stonebridge, and has built a robust global network through collaborations with organizations like EISAI. The newly raised $30 million will be strategically invested to accelerate research and development, enhance their software solutions, and expand technical capabilities across both domestic and international markets. This capital injection arrives on the heels of a remarkable pre-A round last December where the company achieved a fivefold increase in enterprise valuation, underscoring the tremendous market confidence in its innovative approach. Emocog’s mission is clear: to revolutionize digital therapeutics by creating accessible, technology-driven healthcare tools that empower patients and healthcare providers alike. As the company gears up to scale its operations further and reach new global milestones, it is actively seeking visionary professionals and partners to join its journey. Emocog invites stakeholders from across the healthcare and technology sectors to collaborate in shaping a future where cutting-edge digital therapeutics redefine patient care and set new standards in medical innovation.